Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Colorectal Cancer: Update Bulletin [March 2017]

Product Code:
Publication Date:
March 2017

Gain new KOL insights on the latest events happening in colorectal cancer (CRC): an Independent Data Monitoring Committee (IDMC) reported that the Phase III XCITE trial of XBiotech’s Xilonix has no safety concerns and that indications of efficacy are sufficient to recommend proceeding with the study without modification; Northwest Biotherapeutics announced a Phase II clinical trial programme combining DCVax and Keytruda (pembrolizumab; Merck & Co.) for the treatment of CRC with liver metastases; Bristol-Myers Squibb (BMS) announced a clinical collaboration with Janssen Biotech to evaluate the combination of Opdivo (nivolumab) with daratumumab (Darzalex) for the treatment of CRC and other solid tumours; Erbitux (cetuximab; Eli Lilly/Merck Group) has been recommended by the UK’s National Institute for Health and Care Excellence (NICE) as an option for the first-line treatment of patients with EGFR-expressing, RAS wild-type, metastatic CRC in combination with FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) or FOLFIRI (5-fluorouracil, folinic acid and irinotecan).

Business Questions:

  • How do KOLs rate the overall potential of Xilonix as a treatment for CRC?
  • How do KOLs view the design and likely outcome of the Phase III XCITE trial of Xilonix?
  • Where in the CRC treatment paradigm will Xilonix be used?
  • How do KOLs view the use of DCVax in combination with Keytruda for the treatment of CRC?
  • How is the use of immunotherapy in CRC viewed and what could heighten its success?
  • How convincing is the biological rationale for combining Opdivo with daratumumab in CRC treatment?
  • In general terms, how do KOLs view the potential use of Opdivo in combination regimens in CRC?
  • How will the expanded NICE guidance for the use of Erbitux impact its overall use in the UK?
  • How convincing is the clinical case for Erbitux to be used considered for all patients with metastatic CRC, rather than only liver-limited disease?


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved